Patent cliff means pharma will lose $65 billion by 2019, says report

11 December 2014

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, new research shows.

According to research and consulting firm GlobalData’s report, the drugmakers hit hardest will include Japan’s Otsuka (TYO: 4768), the USA’s Eli Lilly (NYSE: LLY) and Anglo-Swedish AstraZeneca (LSE: AZN), with a significant proportion of losses coming in the central nervous system (CNS) treatment sector.

Adam Dion, GlobalData’s analyst covering healthcare industry dynamics, states that Lilly and AstraZeneca have seen profits fall in the CNS therapeutics market since 2010, with the latter losing the greatest share over the past three years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK